Sanofi
SNY
Sanofi (SNY) analyst forecast and price target
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| UBS | Downgraded | Buy → Neutral | — | Jan 16, 2026 |
| Barclays | Downgraded | Overweight → Equal-Weight | — | Jan 6, 2026 |
| Guggenheim | Downgraded | Buy → Neutral | — | Dec 9, 2025 |
| JP Morgan | Downgraded | Overweight → Neutral | — | Dec 8, 2025 |
| Jefferies | Initiated Coverage | Buy | — | Oct 27, 2025 |
| Morgan Stanley | Upgraded | Equal-Weight → Overweight | $58.00 from $56.00 | Sep 8, 2025 |
| Deutsche Bank | Upgraded | Hold → Buy | — | Sep 2, 2025 |
| JP Morgan | Upgraded | Neutral → Overweight | — | Aug 8, 2025 |
| Goldman Sachs | Initiated Coverage | Neutral | $65.00 | Mar 21, 2025 |
| Argus Research | Maintained | Buy | $60.00 from $55.00 | Jul 26, 2024 |
| Morgan Stanley | Initiated Coverage | Equal-Weight | $55.00 | Jan 23, 2024 |
| Argus Research | Maintained | Buy | $60.00 from $55.00 | Mar 27, 2023 |
Frequently asked questions
What is the latest analyst rating on SNY?
On Jan 16, 2026, UBS downgraded Sanofi to Neutral.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.